DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key
word(s): Quarter Results
Eckert & Ziegler: 11% Profit Growth in the 9-Month Period
02.11.2011 / 07:45
---------------------------------------------------------------------
Berlin, November 02, 2011. The first nine months of 2011 developed
extraordinarily successful for the Eckert & Ziegler AG (ISIN DE0005659700),
a specialist for isotope applications in medicine, science and industry.
The revenue of EUR 83.6 million and the profit after taxes and minorities
of EUR 8.8 million mean new record results for the period of time January
to September. Compared with the corresponding period of the previous year
the revenue increased by EUR 2.6 million or 3% and the profit by EUR 0.9
million or 11%. The earnings per share in the 9-month period are EUR 1.68
per share.
The key figures for the third quarter of 2011 alone are also pleasing, even
if in the direct comparison with the same quarter of the previous year a
slight fall in revenue can be recorded from 1% to EUR 27.8 million and with
the profit from 20% to EUR 2.2 million. There are several reasons for this
fall and it is partly due to the exchange rates and the development in
interest rates. In addition, the revenue and income of the previous year
from the Russia project from the Radiation Therapy segment are missing in
2011. Seen in purely operative terms no negative trend can be determined in
the development of business.
The Isotope Products segment accounts for the greatest share of the total
results. The revenue rose by 6% here. All product categories recorded
growth with the exception of the Medical segment. In the ratio to the
revenue the costs only increased less than proportionate owing to economies
of scale. Thus, EBIT could be increased by 16%.
The Radiopharma segment recorded the strongest growth. Increases were also
achieved here in all product lines. In total the segment increased the
revenue by 20% to EUR 19.1 million. As the segment partly profits from very
low marginal costs for the production and sales a large part of the growth
in revenue is reflected in the profits.
The Radiation Therapy segment (previously: Therapy) could not as expected
achieve the record revenue of the previous year. Profits were realised from
the plant sale to Russia in the comparable period of the previous year.
Comparable are therefore only the figures within the year 2011. The revenue
increased slightly compared with the previous quarter. The EBIT with EUR
0.6 million is less than the directly preceding quarter as the development
costs have increased. Detailed statements relating to the Radiation Therapy
segment can be taken from the quarterly report of Eckert & Ziegler BEBIG
S.A. (previously: IBt S.A.), which is published at the same time
(www.bebig.eu).
The revenue with external customers is constant compared with the previous
year in the Environmental Services segment. As however orders are also
placed within the Group and moreover costs were saved there are no losses
suffered any more as opposed to the previous year.
For the fiscal year 2011 the revenue target is EUR 110 to 120 million. The
Board of Directors reinforces its profit forecast of EUR 2.00 per share
(results after taxes and minorities >EUR 10 million). By the end of 2014
the board of directors is expecting a profitable increase in sales to
around EUR 200 million per year.
With around 580 employees the Eckert & Ziegler Group belongs to the largest
providers of isotope components for radiation therapy and nuclear medicine
worldwide.
If you have any questions please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com
End of Corporate News
---------------------------------------------------------------------
02.11.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
---------------------------------------------------------------------
144300 02.11.2011
DGAP-News: Eckert & Ziegler: 11% Profit Growth in the 9-Month Period
| Source: EQS Group AG